Irinotecan (CPT-11) metabolites in human bile and urine

Clinical Cancer Research

Volumn 2, Issue 12, 1996, Pages 1943-1949

  Lokiec, François ^a   Du Sorbier, Bertrand Monegier ^b   Sanderink, Ger Jan ^b  

^a CENTRE RENÉ HUGUENIN   (France)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DRUG METABOLITE; IRINOTECAN;

ADULT; ARTICLE; CASE REPORT; COLON CARCINOMA; DRUG BILE LEVEL; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BILE; CAMPTOTHECIN; COLONIC NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MASS SPECTROMETRY; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 12644265333     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Slichenmeyer, W. J., Rowinsky, E. K., Donehower, R. C., and Kaufmann, S, H. The current status of camptothecin analogues as antitumor agents. J. Natl Cancer Inst., 85: 271-291, 1993.
2. Potmesil, M. Camptothecins from bench research to hospital wards. Cancer Res., 54: 1431-1439, 1994.
3. Kaneda, N., Nagato, H., Furuta, T., and Yokokura T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res., 50: 1715-1720, 1990.
4. Kawato, Y., Aonuma, M. Hirota, Y, Kuga, H., and Sato, K. Intracellular roles of SN-38, an active metabolite of the camptothecin derivative CPT-11, in the anti-tumor effect of CPT-11. Cancer Res., 51: 4187-4191, 1991.
5. Tsuji, T., Kaneda, N., Kado, K.,. Yokokura, T., Yoshimoto, T., and Tsuru, D. CPT-11 converting enzyme from rat serum: purification and some properties. J. Pharmacobio-Dyn., 14: 341-349, 1991.
6. Kaneda, N., and Yokokura T. Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res., 50: 1721-1725, 1990.
7. Atsumi, R., Suzuki, W., and Hakusui, H. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica. 21: 1159-1169, 1991.
8. Lokiec, F., Canal, P. Gay, C., Chatelut, E., Armand, J-P, Roché, H., Bugat, R, Gonçalvès, E., and Mathieu-Boué, A. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine Cancer Chemother. Pharmacol., 36: 79-82, 1995.
9. Rivory, L. P., and Robert, J. Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother. Pharmacol., 36: 176-179, 1995.
10. Gupia, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E., and Ratain, M. J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res., 54: 3723-3725, 1994.
11. Barilero, I., Gandia, D., Armand, J-P., Mathieu-Boué, A , Re, M., Gouyette, A., and Chabot, G. G. Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients. J. Chromatogr., 575: 275-280, 1992.
12. Masumoto, H., Ohta, S., and Hirobe, M. Application of chemical cytochrome P-450 systems to studies on drug metabolism. IV. Mechanism of piperidine metabolism pathways via an iminium intermediate. Drug Metab. Dispos., 19: 768-780, 1991.
13. Gandia, D., Abigerges, D., Armand, A. P., Chabot, G., Da Costa, L., De Forni, M, Mathiue-Boué, A., and Hérait, P. CPT-11-induced cholinergic effects in cancer patients. J. Clin. Oncol., 11: 196-197, 1993.
14. Kawato, Y., Sekiguchi, M., Akahane, K., Tsutomi, Y., Hirota, Y., Kuga, H., Suzuki, W., Hakusui, H., and Sato, K. Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats. J. Pharm. Pharmacol., 45: 444-448, 1993